Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

November 4, 2021

Study Completion Date

May 23, 2024

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Durvalumab

1500mg via IV infusion every 4 weeks for up to 3 doses/cycles

DRUG

Tremelimumab

75mg via IV infusion every 4 weeks

RADIATION

Thoracic Radiation

5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction

PROCEDURE

lobectomy

patients may proceed to surgery post drug and radiation intervention for lung lobectomy

DRUG

Standard of care adjuvant chemotherapy

patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery

Trial Locations (2)

21224

Johns Hopkins Bayview Medical Center, Baltimore

Unknown

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER